Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Case Report

Löffler’s Endomyocarditis in the Idiopathic Hypereosinophilic Syndrome

Corssmit E.P.M.a · Trip M.D.a, b · Durrer J.D.b

Author affiliations

Departments of aInternal Medicine and bCardiology, Academic Medical Center, Amsterdam, The Netherlands

Related Articles for ""

Cardiology 1999;91:272–276

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Case Report

Published online: October 25, 1999
Issue release date: October 1999

Number of Print Pages: 5
Number of Figures: 4
Number of Tables: 0

ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)

For additional information: https://www.karger.com/CRD

Abstract

The idiopathic hypereosinophilic syndrome (HES) is a leukoproliferative disorder characterized by sustained eosinophilia (> 1.5 × 109/l) and (multi-)organ dysfunction caused by infiltration of eosinophils. Especially the heart is frequently affected. In this report, we describe 2 patients with HES and Löffler’s endomyocarditis. Prednisone is the drug of choice for treatment. Both our patients responded very well to prednisone and came into remission. If prednisone fails, there are other therapeutic options like myelosuppressive drugs (hydroxyurea and vincristine) or interferon-α. We review the literature with regard to clinical presentation, diagnosis and treatment.


References

  1. Löffler W: Endocarditis parietalis fibroplastica mit Bluteosinophilie. Schweiz Med Wochenschr 1936;65:817–820.
  2. Chusid MJ, Dale DC, West BC, Wolff SM: The hypereosinophilic syndrome: Analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975;54:1–27.
  3. Olson EGJ, Spry CJF: Relation between eosinophilia and endomyocardial disease. Prog Cardiovasc Dis 1985;27:241–254.
    External Resources
  4. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH: NIH Conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982;97:78–92.
  5. Spry CJ, Davies J, Tai PC, Olsen EG, Oakley CM, Goodwin JF: Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 1983;52:1–22.
  6. Roberts WC, Liegler G, Carbone PP: Endomyocardial disease and eosinophilia. A clinical and pathologic spectrum. Am J Med 1969;46:28–42.
  7. Parillo JE, Borer JS, Henry WL, Wolff SM, Fauci AS: The cardiovascular manifestations of the hypereosinophilic syndrome. Am J Med 1979;67:572–582.
  8. Parillo JE, Fauci AS, Wolff SM: Therapy of the hypereosinophilic syndrome. Ann Intern Med 1978;89:167–172.
  9. Olsen EGJ, Spry CJF: Relation between eosinophilia and endomyocardial disease. Prog Cardiovasc Dis 1985;27:241–243.
    External Resources
  10. Davidson AG, Thompson PJ, Davies J, Corrin B, Turner-Warwick M: Prominent pericarditis and myocardial lesions in the Churg-Strauss syndrome (allergic granulomatosis and angiitis). Thorax 1983;38:793–795.
    External Resources
  11. Sanderson CJ: Interleukin-5, eosinophils and disease. Blood 1992;79:3101–3109.
  12. Schleimer RP, Bochner BS: The effects of glucocorticoids on human eosinophils. Allergy Clin Immunol 1994;94:1202–1213.

Article / Publication Details

First-Page Preview
Abstract of Case Report

Published online: October 25, 1999
Issue release date: October 1999

Number of Print Pages: 5
Number of Figures: 4
Number of Tables: 0

ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)

For additional information: https://www.karger.com/CRD


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.